Eli Lilly and Company (NYSE:LLY) Holdings Increased by Tokio Marine Asset Management Co. Ltd.

Key Points

• Tokio Marine Asset Management Co. Ltd. increased its stake in Eli Lilly and Company by 2.3% in Q1, owning 57,865 shares valued at approximately $47.79 million, making it the firm's 11th largest position.
• Directors J Erik Fyrwald and Jamere Jackson purchased shares of Eli Lilly stock for a total of over $1.13 million, reflecting a commitment from company insiders to strengthen their positions.
• Eli Lilly reported strong financial results with an EPS of $6.31 for the quarter, exceeding estimates, alongside a 37.6% year-over-year increase in revenue of $15.56 billion.

Tokio Marine Asset Management Co. Ltd. boosted its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 2.3% during the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 57,865 shares of the company's stock after buying an additional 1,307 shares during the quarter. Eli Lilly and Company makes up about 1.7% of Tokio Marine Asset Management Co. Ltd.'s holdings, making the stock its 11th biggest position. Tokio Marine Asset Management Co. Ltd.'s holdings in Eli Lilly and Company were worth $47,791,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of LLY. NFP Retirement Inc. raised its holdings in Eli Lilly and Company by 0.5% in the 1st quarter. NFP Retirement Inc. now owns 4,581 shares of the company's stock valued at $3,783,000 after acquiring an additional 22 shares during the last quarter. S Bank Fund Management Ltd acquired a new position in Eli Lilly and Company in the 1st quarter valued at $7,768,000. National Pension Service raised its holdings in Eli Lilly and Company by 4.8% in the 1st quarter. National Pension Service now owns 1,627,597 shares of the company's stock valued at $1,344,249,000 after acquiring an additional 74,207 shares during the last quarter. Klingman & Associates LLC raised its holdings in Eli Lilly and Company by 9.3% in the 1st quarter. Klingman & Associates LLC now owns 1,886 shares of the company's stock valued at $1,558,000 after acquiring an additional 161 shares during the last quarter. Finally, Dagco Inc. acquired a new position in Eli Lilly and Company in the 1st quarter valued at $135,000. Hedge funds and other institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Stock Up 2.5%

NYSE LLY traded up $17.08 on Friday, hitting $701.51. 8,211,278 shares of the stock traded hands, compared to its average volume of 6,346,453. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. The stock has a 50-day moving average of $764.55 and a 200 day moving average of $794.69. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $972.53. The company has a market capitalization of $663.95 billion, a P/E ratio of 45.85, a price-to-earnings-growth ratio of 0.95 and a beta of 0.44.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%. The business had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same period in the prior year, the company posted $3.92 EPS. The business's revenue was up 37.6% compared to the same quarter last year. As a group, analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be given a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date of this dividend is Friday, August 15th. Eli Lilly and Company's dividend payout ratio is currently 39.22%.

Analyst Ratings Changes

LLY has been the subject of a number of research analyst reports. Deutsche Bank Aktiengesellschaft dropped their price objective on Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating for the company in a report on Monday, August 11th. Morgan Stanley reaffirmed an "overweight" rating and set a $1,135.00 price target (up from $1,133.00) on shares of Eli Lilly and Company in a research report on Thursday, July 10th. Leerink Partners reaffirmed a "market perform" rating and set a $715.00 price target on shares of Eli Lilly and Company in a research report on Thursday, August 7th. Leerink Partnrs cut shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research report on Thursday, August 7th. Finally, HSBC cut shares of Eli Lilly and Company from a "buy" rating to a "reduce" rating and decreased their price target for the stock from $1,150.00 to $700.00 in a research report on Monday, April 28th. One analyst has rated the stock with a sell rating, five have issued a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $964.88.

Insider Buying and Selling at Eli Lilly and Company

In related news, Director Gabrielle Sulzberger purchased 117 shares of the company's stock in a transaction dated Tuesday, August 12th. The shares were acquired at an average cost of $641.18 per share, for a total transaction of $75,018.06. Following the transaction, the director owned 2,703 shares of the company's stock, valued at $1,733,109.54. This trade represents a 4.52% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Jamere Jackson acquired 200 shares of Eli Lilly and Company stock in a transaction that occurred on Friday, August 8th. The shares were bought at an average price of $639.56 per share, with a total value of $127,912.00. Following the transaction, the director directly owned 9,402 shares in the company, valued at approximately $6,013,143.12. This trade represents a 2.17% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders have purchased 4,514 shares of company stock worth $2,894,841. 0.13% of the stock is owned by company insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.